David L Wyles1. 1. Division of Infectious Diseases, Denver Health Medical Center, 660 Bannock St, MC 4000, Denver, CO, 80204, USA. David.Wyles@dhha.org.
Abstract
PURPOSE OF REVIEW: This review provides an overview of HCV resistance-associated substitutions (RASs) with a focus on NS3 protease and NS5A inhibitor resistance. Treatment approaches for managing resistance are also covered including the use of newly approved therapies with improved resistance profiles. RECENT FINDINGS: HCV RASs are frequently selected if the patient is not cured during treatment; NS5A RASs persist for prolonged periods of time (years) after treatment failure and may adversely impact retreatment responses. Newly approved regimens with improved potency and resistance profiles are less impacted by resistance and provide the best retreatment options for patients who previously failed DAA therapy. The clinical impact of HCV RASs has been lessened significantly with the introduction of new DAA treatment regimens. Routine testing for resistance is unlikely to impact retreatment approaches if newer regimens are accessible. Knowledge of factors, such as the presence of cirrhosis and prior treatment regimens, remain as the key to optimizing retreatment approaches.
PURPOSE OF REVIEW: This review provides an overview of HCV resistance-associated substitutions (RASs) with a focus on NS3 protease and NS5A inhibitor resistance. Treatment approaches for managing resistance are also covered including the use of newly approved therapies with improved resistance profiles. RECENT FINDINGS: HCV RASs are frequently selected if the patient is not cured during treatment; NS5A RASs persist for prolonged periods of time (years) after treatment failure and may adversely impact retreatment responses. Newly approved regimens with improved potency and resistance profiles are less impacted by resistance and provide the best retreatment options for patients who previously failed DAA therapy. The clinical impact of HCV RASs has been lessened significantly with the introduction of new DAA treatment regimens. Routine testing for resistance is unlikely to impact retreatment approaches if newer regimens are accessible. Knowledge of factors, such as the presence of cirrhosis and prior treatment regimens, remain as the key to optimizing retreatment approaches.
Entities:
Keywords:
Direct acting antivirals; HCV; Resistance-associated substitutions
Authors: Ira M Jacobson; Gregory J Dore; Graham R Foster; Michael W Fried; Monica Radu; Vladimir V Rafalsky; Larysa Moroz; Antonio Craxi; Monika Peeters; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Guy De La Rosa; Ronald Kalmeijer; Jane Scott; Rekha Sinha; Maria Beumont-Mauviel Journal: Lancet Date: 2014-06-04 Impact factor: 79.321
Authors: Rosemary M McCloskey; Richard H Liang; Jeffrey B Joy; Mel Krajden; Julio S G Montaner; P Richard Harrigan; Art F Y Poon Journal: J Infect Dis Date: 2014-11-10 Impact factor: 5.226
Authors: Eric J Lawitz; Hadas Dvory-Sobol; Brian P Doehle; Angela S Worth; John McNally; Diana M Brainard; John O Link; Michael D Miller; Hongmei Mo Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191
Authors: Chunfu Wang; Haichang Huang; Lourdes Valera; Jin-Hua Sun; Donald R O'Boyle; Peter T Nower; Lingling Jia; Dike Qiu; Xin Huang; Aneela Altaf; Min Gao; Robert A Fridell Journal: Antimicrob Agents Chemother Date: 2012-01-03 Impact factor: 5.938
Authors: Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes Journal: Hepatology Date: 2014-07-28 Impact factor: 17.425
Authors: Marc Bourlière; Stuart C Gordon; Steven L Flamm; Curtis L Cooper; Alnoor Ramji; Myron Tong; Natarajan Ravendhran; John M Vierling; Tram T Tran; Stephen Pianko; Meena B Bansal; Victor de Lédinghen; Robert H Hyland; Luisa M Stamm; Hadas Dvory-Sobol; Evguenia Svarovskaia; Jie Zhang; K C Huang; G Mani Subramanian; Diana M Brainard; John G McHutchison; Elizabeth C Verna; Peter Buggisch; Charles S Landis; Ziad H Younes; Michael P Curry; Simone I Strasser; Eugene R Schiff; K Rajender Reddy; Michael P Manns; Kris V Kowdley; Stefan Zeuzem Journal: N Engl J Med Date: 2017-06-01 Impact factor: 91.245
Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245
Authors: Ernest Asante-Appiah; Paul Ingravallo; Patricia McMonagle; Karin Bystol; Ellen Xia; Stephanie Curry; Ping Qiu; Stuart Black; Robert Chase; Rong Liu; Fred Lahser Journal: Antimicrob Agents Chemother Date: 2019-09-16 Impact factor: 5.191
Authors: Ernest Asante-Appiah; Rong Liu; Stephanie Curry; Patricia McMonagle; Sony Agrawal; Donna Carr; Laura Rokosz; Frederick Lahser; Karin Bystol; Robert Chase; Stuart Black; Eric Ferrari; Paul Ingravallo; Ling Tong; Wensheng Yu; Joseph Kozlowski Journal: Antimicrob Agents Chemother Date: 2018-10-24 Impact factor: 5.191
Authors: Vanessa D Costa; Carlos E Brandão-Mello; Estevão P Nunes; Pedro Guilherme Corôa Dos Santos Silva; Lia Laura Lewis Ximenez de Souza Rodrigues; Elisabeth Lampe; Francisco Campello do Amaral Mello Journal: PLoS One Date: 2019-05-07 Impact factor: 3.240
Authors: Karen K Kyuregyan; Vera S Kichatova; Anastasiya A Karlsen; Olga V Isaeva; Sergei A Solonin; Stefan Petkov; Morten Nielsen; Maria G Isaguliants; Mikhail I Mikhailov Journal: Biomedicines Date: 2020-04-07
Authors: Soraia M Machado; Aline G Vigani; Andrea G Leite; Ana Claudia M Diaz; Paulo Roberto A Ferreira; Dimas Carnaúba-Júnior; Simone B Tenore; Carlos Eduardo Brandão-Mello; Mario P Gonzalez; Fabiana Siroma; Kleber D Prado; Delzi V Nunes; Gaspar Lisboa-Neto; João Renato R Pinho; Fernanda M Malta; Raymundo S Azevedo; Steven S Witkin; Maria Cássia Mendes-Correa Journal: Medicine (Baltimore) Date: 2020-07-24 Impact factor: 1.817